[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629243":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":11,"centralContacts":28,"locations":37,"responsibleParty":54,"collaborators":11,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":11,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":11,"studyType":69,"phases":70,"briefSummary":73,"conditions":74,"keywords":11,"overallStatus":40,"whyStopped":11,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"N.N. Alexandrov National Cancer Centre","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"PARPi + Bev","EXPERIMENTAL",null,[13],"Drug: PARP inhibitor + Bevacizumab",{"label":15,"type":10,"description":11,"interventionNames":16},"PARPi",[17],"Drug: PARP inhibitor",[19,24],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","PARP inhibitor + Bevacizumab","Patients will receive 6 courses of chemotherapy according to the regimen of platinum drug + paclitaxel + bevacizumab (≥3 cycles) every 21 days. In case of a complete or partial response maintenance therapy is carried out until disease progression or intolerable toxicity or for 2 years to the regimen of PARP inhibitor + bevacizumab.",[9],{"type":20,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"PARP inhibitor","Patients will receive 6 courses of chemotherapy according to the regimen of platinum drug + paclitaxel every 21 days. In case of a complete or partial response maintenance therapy of PARP inhibitor is carried out until disease progression or intolerable toxicity or for 2 years.",[15],[29,34],{"name":30,"role":31,"phone":32,"phoneExt":11,"email":33},"Hanna Trukhan","CONTACT","80291985715","annavladimir@rambler.ru",{"name":35,"role":31,"phone":11,"phoneExt":11,"email":36},"Sergey Mavrichev","smavrichev71@gmail.com",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"N.N. Alexandrov National Caner Centre","RECRUITING","Minsk","Lesnoy","223040","Belarus","BY",{"type":47,"coordinates":48},"Point",[49,50],27.56653,53.90019,{"lat":50,"lon":49},[53],{"name":30,"role":31,"phone":32,"phoneExt":11,"email":33},{"type":55,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100629243","phase-2-parp-poly-adp-ribose-polymerase-inhibitor-with-or-without-angiogenesis-inhibitor-in-homologous-recombination-deficient-primary-ovarian-cancer-fallopian-tube-cancer-or-primary-peritoneal-cancer-100629243",false,"NCT07472140","PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer","To Develop and Implement The Scope of Medical Care for Homologous Recombination Deficient Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer of the III-IV Stages Using Maintenance Therapy With PARP Inhibitor Combined With Angiogenesis Inhibitor.","Inclusion Criteria:\n\n* Age ≥18-≤75 years.\n* Histologically confirmed diagnosis of serous or endometrioid high-grade ovarian cancer, fallopian-tube cancer or primary peritoneal cancer.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Possibility of performing diagnostic laparoscopy or cytoreductive surgery.\n* Presence of homologous recombination deficiency (HRD).\n* No contraindications to chemotherapy, or bevacizumab.\n* Signed informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Presence of another active malignant invasive neoplasm.\n* Pregnancy or lactation period.\n* Disease progression during treatment.","FEMALE","18 Years","75 Years",{"count":67,"type":68},120,"ESTIMATED","INTERVENTIONAL",[71,72],"PHASE2","PHASE3","This is a randomized trial evaluating the results of using of PARP inhibitor combined with angiogenesis inhibitor. in patients with homologous recombination deficient primary ovarian cancer, fallopian-tube cancer, or primary peritoneal cancer of the III-IV stages.",[75,76,77],"Ovarian Cancer","Fallopian Tube Cancers","Primary Peritoneal Cancer","2026-03-11",{"date":80,"type":81},"2026-03-16","ACTUAL",{"date":83,"type":81},"2025-07-01",{"date":85,"type":68},"2033-06-30",{"name":5,"class":6},1]